Dengue fever

Possible Breakthrough in Cardiovascular Disease Diagnostics for Europe and the European Union

Retrieved on: 
金曜日, 12月 16, 2022
Peptide, Nanoparticle, Hereditary nonpolyposis colorectal cancer, SingHealth, Convergence (sustainability science), Degenerative disease, ICMR, Union, Prostate, Biomarker, Acute coronary syndrome, Patient, Hospital, Cardiovascular disease, FDA, Dengue fever, Death, Coronavirus Scientific Advisory Board (Turkey), Nanotechnology, Gold, Electronics, Machine learning, USD, Medical research, Pharmaceutical industry, Medical imaging, Science, Myoglobin, Malaria

Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.

Key Points: 
  • Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.
  • The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays.
  • The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving highly accurate and fast results.
  • According to the European Heart Network, each year cardiovascular disease causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union.

Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States

Retrieved on: 
金曜日, 12月 16, 2022
Peptide, Nanoparticle, Hereditary nonpolyposis colorectal cancer, SingHealth, Convergence (sustainability science), Degenerative disease, ICMR, Human services, Prostate, Biomarker, Acute coronary syndrome, Patient, Hospital, Cardiovascular disease, FDA, Dengue fever, Health, Multimedia, Coronavirus Scientific Advisory Board (Turkey), Nanotechnology, Gold, Electronics, Machine learning, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, USD, Medical research, Pharmaceutical industry, Medical imaging, Science, Myoglobin, Malaria

Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.

Key Points: 
  • Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers.
  • The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays.
  • The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving highly accurate and fast results.
  • According to the U.S. Department of Health & Human Services, a total of 697000 people died in 2020, one person dies every 34 seconds in the US from cardiovascular disease.

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

Retrieved on: 
木曜日, 12月 8, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, VE, Infection, Fever Dream, Hospital, Immunization, Anaphylaxis, Headache, Disease, Syncope, Dengue fever, Medication package insert, Woman, Dengue virus, Contraindication, Fiscal, Risk, Vaccination, CHMP, EC, Union, Prednisone, Royal commission, Friends, TAK, Myalgia, Holiday, European Directive on Traditional Herbal Medicinal Products, Climate change, Birth, Immunodeficiency, Hyperventilation, Overalls, Science, Travel, HIV, Excipient, European Medicines Agency, VCD, Patient, Tropical medicine, Hypersensitivity, Incidence, European Commission, Safety, Weakness, Fever, Vaccine, Takeda, EU

Guidance for use: QDENGA should be administered by subcutaneous injection preferably in the upper arm in the region of deltoid.

Key Points: 
  • Guidance for use: QDENGA should be administered by subcutaneous injection preferably in the upper arm in the region of deltoid.
  • Appropriate medical treatment and supervision must always be readily available in the event of a rare anaphylactic reaction following administration of the vaccine.
  • 2020;395:1423-1433.
    x Tricou, V. Efficacy and Safety of Takedas Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up.
  • December 2022.
    xiv Efficacy, Safety and Immunogenicity of Takedas Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES).

Electronic Skin Patches Sales to Reach USD 29 Billion by 2027, Next-Gen Electronic Skin Patches to Witness Tremendous Demand. Abbott, Dexcom, GE, and Philips Set to Capatilize the Opportunity - Arizton

Retrieved on: 
水曜日, 12月 14, 2022
Escherichia coli, Chemistry, HIV, West Nile virus, Dengue fever, Skin, Infection, Patient, Radiation, Zika virus, Pandemic, Tuberculosis, Epidemic, Orthohantavirus, Science and technology in Asia, Health care, Lyme disease, COVID-19, WHO, UV, Severe acute respiratory syndrome, Cosmetics, Vaccine, Zika fever

A Rise in the Usage of Electronic Skin Patches for Drug Delivery & Cosmetics.

Key Points: 
  • A Rise in the Usage of Electronic Skin Patches for Drug Delivery & Cosmetics.
  • The emergence of electronic skin patches has been widely helpful in managing an individual's health either on their own or in any healthcare setting.
  • To manage patients suffering from various infectious diseases, significant advancements are likely to happen in electronic skin patches.
  • Electronic skin patches are used as cosmetic delivery systems for providing active ingredients that help maintain the ideal nature of the skin.

IDENTIFYSENSORS BIOLOGICS REACHES BREAKTHROUGH SENSITIVITY LEVELS WITH NEW DIGITAL DIAGNOSTICS PLATFORM

Retrieved on: 
水曜日, 12月 7, 2022
Genome, Stomach, HIV, RT-PCR, Lyme disease, Mobile, Rotavirus, Hepatitis, Patient, COVID, Gonorrhea, Research, Digital, PCR, Food, FDA, Yellow fever, COVID-19, RSV, Infection, MRSA, Vaccine, Pharmaceutical industry, Adenoviridae, Herpes simplex, Chlamydia, Dengue fever, Norovirus

CLEVELAND, Dec. 7, 2022 /PRNewswire/ -- IdentifySensors Biologics has completed preliminary clinical tests of positive COVID-19 samples using new graphene digital sensors, which demonstrate level-of-detection capabilities four times more sensitive than PCR tests.

Key Points: 
  • The samples were then diluted to the preliminary limit of detection of 200 copies per milliliter and retested using Check4.
  • The research demonstrates that infections, such as COVID, RSV and influenza, can soon be diagnosed well before patients develop symptoms, said IdentifySensors Biologics Cofounder and CEO Gregory Hummer M.D.
  • Digital graphene sensors inside the cartridges target conserved regions of the genome allowing for high sensitivity and specificity.
  • The company's technology has expanded into multiple industries and applications, such as pathogen diagnostics and testing for food contamination.

NLT Partners with UC San Diego to Develop a Dynamic Infectious Disease Risk Platform

Retrieved on: 
木曜日, 11月 24, 2022
UC San Diego School of Global Policy and Strategy, Wellcome Trust, Risk, Trust law, Infection, Dean (education), Public health, European Space Agency, NLT, UC, Climate change, World Health Organization, Copernicus Climate Change Service, University of California, San Diego, Australian Space Agency, UNICEF, Health, University, WHO, Google Earth, ESA, Fever, Policy, Vaccine, Dengue fever

WASHINGTON, Nov. 23, 2022 /PRNewswire/ -- Dengue fever is one of the most common and rapidly spreading vector-borne viral diseases, with major public health and economic consequences, particularly in tropical and subtropical regions. According to the World Health Organization (WHO), the global burden of Dengue increased eightfold over the last two decades, due in part to climate change and anthropogenic activities. With almost half of the world's population living in areas with a risk of Dengue fever and with its increasing spread, there is an overwhelming need for near real-time prediction and effective monitoring of Dengue transmission rates and the ability to estimate the public health resources required for disease prevention and treatment.

Key Points: 
  • New Light Technologies Inc. (NLT) will develop, together with researchers from the University of California, San Diego (UC San Diego), a Dynamic Infectious Disease Risk Platform to provide decision-makers a data-driven predictive tool for early warning of likely imminent spikes in Dengue fever across tropical Latin America.
  • UC San Diego School of Global Policy and Strategy faculty member Gordon McCord is partnering with NLT to develop an online data analytics platform to support decision makers with spatial and temporal patterns of existing and forecasted Dengue fever outbreaks.
  • "Our hope is that this platform will influence positive climate-focused policy change by the governing administrative body of the affected areas," said Goldblatt.
  • According to UC San Diego doctoral student Gabriel Carrasco-Escobar, the platform will also provide key insights for preventive decision making.

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 11月 7, 2022
Adult, Research, Risk, Development, Population, Death, Delta, State Administrative Expenses, Company, Standard of care, Administration, Security (finance), Rest, Immunity, Plasma, Personal income in the United States, Clinical trial, Roche, Ritonavir, Annual general meeting, Society, Tropical medicine, Alpha, Atea, Patient, COVID-19, Income, Vaccine, Doctor of Philosophy, Nasdaq, NS5A, Merck, DENV, Dengue fever, RZR, Hospital, HIV disease progression rates, Initiation, American Society of Tropical Medicine and Hygiene, Food, GLOBE, Fever Dream, Second generation, Severe acute respiratory syndrome coronavirus 2, Income tax, Immunodeficiency, HCV, Founder, Hepatitis C, Safety, BID, Disease, Viral load, Therapy, Cost sharing, SOC, Pharmaceutical industry, Vitro, Omicron

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.   

Key Points: 
  • This year, we have made substantial progress advancing our three clinical candidates, which will make 2023 a pivotal year.
  • Furthermore, monoclonal antibodies are largely ineffective against the newer COVID-19 variants leaving many without treatment options.
  • Studies conducted by Atea have shown in vitro synergy from the combination of bemnifosbuvir and RZR in inhibiting HCV replication.
  • Cash, Cash Equivalents and Marketable Securities: $665.0 million at September 30, 2022 compared to $764.4 million at December 31, 2021.

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

Retrieved on: 
木曜日, 11月 3, 2022
Infection, Private Securities Litigation Reform Act, Founder, Society, Biology, FDA, Adult, Antibody-dependent enhancement, Annual report, Virology, HCV, Disease, SEC, SAD, Tropical medicine, Transactions of the Royal Society of Tropical Medicine and Hygiene, Dengue fever, ADE, Ageing, Food, World, Degenerative disease, MAD, GLOBE, Dengue virus, Fever Dream, Plasma, Patient, Pharmacokinetics, Federal Food, Drug, and Cosmetic Act, Doctor of Philosophy, Virus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, World Health Organization, COVID-19, Annual general meeting, Respiratory syncytial virus, Severe acute respiratory syndrome coronavirus 2, RNA, Atea, RSV, Biochemistry, Safety, Poster, Nasdaq, NDA, Cross-reactivity, Tourism, Risk, PK, Pharmaceutical industry, Vaccine

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical Medicine & Hygiene (ASTMH) 2022 Annual Meeting in Seattle, Washington.

Key Points: 
  • Based on these data, we anticipate that AT-752 may have the potential to rapidly inhibit dengue virus replication across all serotypes (1-5).
  • The first study is a global, randomized, double-blind, placebo-controlled Phase 2 trial in adult patients with dengue virus infection.
  • AT-752, a novel, orally administered direct-acting antiviral derived from Ateas purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752 for the treatment of dengue virus infection.

EQS-News: This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

Retrieved on: 
金曜日, 10月 28, 2022
Eye, IND, Dengue fever, Company, Bird, Virus, Drug development, Pox, Skin cream, Death, Rash, US, Safety, CGMP, Gilead, Disease, VZV, Food, Shingles, HCV, Hepatitis B virus, HIV, Patient, Technology, HBV, Remdesivir, Keratitis, Food and Drug Administration, Research, COVID-19, Degenerative disease, Hepatitis C, Influenza, FDA, Consultant, NYSE, Monkeypox, US FDA, Advertising, EKC, Vaccine, Pharmaceutical industry, West Nile virus, Rabies

Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.

Key Points: 
  • Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.
  • NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
  • The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
火曜日, 10月 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.